< back to release list

Raze Therapeutics Appoints Mikel Moyer, PhD, as Vice President, Molecular Discovery

– Drug Discovery Leader with Extensive Oncology Experience –

Cambridge, Mass., October 28, 2014 – Raze Therapeutics, a biotechnology company leading the discovery and development of a new class of oncology therapeutics that target key metabolic pathways, today announced the appointment of Mikel Moyer, PhD, as Vice President, Molecular Discovery, effective November 1, 2014.

“Dr. Moyer brings proven leadership, deep experience, and a strong record of success to Raze as we build a pipeline of innovative oncology therapeutics that target mitochondrial one-carbon metabolism,” said Jason Rhodes, acting Chief Executive Officer of Raze Therapeutics.

“I am delighted to join Raze at this exciting time as we leverage the company’s powerful drug discovery platform to rapidly advance drug development programs directed to solid tumors and hematological malignancies,” said Dr. Moyer.

Dr. Moyer has more than 25 years of experience in the biopharmaceutical industry. Prior to joining Raze, Dr. Moyer held leadership positions at Loxo Oncology, Epizyme, the Broad Institute, and Pfizer. Dr. Moyer obtained a BS from the University of Michigan and a PhD in synthetic organic chemistry from the University of California, Berkeley.

About Mitochondrial One-Carbon (1C) Metabolism

The function of mitochondrial one-carbon (1C) metabolism is to drive rapid biomass accumulation. Through selective aberrant expression or genetic mutations, cancer cells activate these pathways to form aggressive tumors. Prior to newly elucidated discoveries about 1C metabolism by Raze’s founders, the central role of these pathways in cancer growth was unappreciated, and 1C metabolism was not specifically targeted for cancer drug development. The new insights by Raze’s founders have led to the identification of targets in 1C metabolism that are highly specific to tumors and when inhibited selectively halt anabolic processes and the ability of tumors to accumulate biomass, offering the promise of targeted new cancer drugs.

About Raze Therapeutics

Raze Therapeutics is dedicated to the discovery and development of a new class of oncology therapeutics that target fundamental metabolic pathways essential to cancer growth and survival. By selectively targeting one-carbon (1C) metabolism using its proprietary platform, Raze is developing a pipeline of 1C metabolism therapeutics across a range of solid and hematologic cancers, including genetically defined cancers. Raze is led by an experienced management team with a proven track record for building successful biotech companies and recognized scientific leaders in metabolism and cancer biology. The company was founded by Atlas Venture as a seed company and is funded by leading life sciences investors, including Atlas Venture, MPM Capital, MS Ventures, Partners Innovation Fund, Astellas Venture Management, and Novartis. For more information, please visit our website at: www.razetx.com or follow us on Twitter at @RazeTx.

 

For information contact:

Feinstein Kean Healthcare
Jess Rowlands, (202) 729-4089
jessica.rowlands@fkhealth.com